Adjuvant high‐dose chemotherapy supported by peripheral blood stem cell transplantation for high‐risk cervical carcinoma

. Dueñas‐González A, Lara Medina FU, Solorza‐Luna G, de la Garza‐Salazar J, Sobrevilla‐Calvo PJ. Adjucant high‐dose chemotherapy supported by peripheral blood stem cell transplantation for high‐risk cervical cancer. Cervical carcinoma is a common disease for which the prognosis has not been substantially improved with standard locoregional treatments. Three stage IB patients with untreated cervical carcinoma were treated with high‐dose chemotherapy and refrigerated peripheral blood stem cell support using the ICE program (Ifosfamide 10 g/m2 plus mesna at 100% of the ifosfamide dose; Carboplatin at 1.5 g/m2 and Etoposide 2.1 g/m2). Patients received the treatment in an adjuvant setting after radical hysterectomy with pelvic lymph‐node dissection and postoperative cisplatin‐based standard‐dose chemotherapy. All patients underwent postoperative radiotherapy. The treatment was well‐tolerated, all patients had rapid hematologic recovery, and the most frequent complications were grade 3 mucositis and neutropenic fever. The three patients are disease‐free at 58, 60, and 63 months of follow‐up. Our results show that adjuvant high‐dose chemotherapy could be effective to reduce the likelihood of relapse in high‐risk patients. High‐dose chemotherapy deserves a formal evaluation in high‐risk cervical cancer.